chr9-95107254-C-T

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_000136.3(FANCC):​c.1345G>A​(p.Val449Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0042 in 1,613,862 control chromosomes in the GnomAD database, including 224 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V449A) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.021 ( 123 hom., cov: 33)
Exomes 𝑓: 0.0025 ( 101 hom. )

Consequence

FANCC
NM_000136.3 missense

Scores

3
15

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts U:1B:13O:1

Conservation

PhyloP100: 1.06

Publications

20 publications found
Variant links:
Genes affected
FANCC (HGNC:3584): (FA complementation group C) The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group C. [provided by RefSeq, Jul 2008]
AOPEP (HGNC:1361): (aminopeptidase O (putative)) This gene encodes a member of the M1 zinc aminopeptidase family. The encoded protein is a zinc-dependent metallopeptidase that catalyzes the removal of an amino acid from the amino terminus of a protein or peptide. This protein may play a role in the generation of angiotensin IV. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Oct 2010]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.0033890307).
BP6
Variant 9-95107254-C-T is Benign according to our data. Variant chr9-95107254-C-T is described in ClinVar as Benign. ClinVar VariationId is 134298.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.0701 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
FANCCNM_000136.3 linkc.1345G>A p.Val449Met missense_variant Exon 14 of 15 ENST00000289081.8 NP_000127.2 Q00597A0A024R9N2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
FANCCENST00000289081.8 linkc.1345G>A p.Val449Met missense_variant Exon 14 of 15 1 NM_000136.3 ENSP00000289081.3 Q00597

Frequencies

GnomAD3 genomes
AF:
0.0208
AC:
3169
AN:
152126
Hom.:
123
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0722
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00661
Gnomad ASJ
AF:
0.00202
Gnomad EAS
AF:
0.000771
Gnomad SAS
AF:
0.000207
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.0158
Gnomad NFE
AF:
0.000588
Gnomad OTH
AF:
0.0100
GnomAD2 exomes
AF:
0.00609
AC:
1527
AN:
250656
AF XY:
0.00459
show subpopulations
Gnomad AFR exome
AF:
0.0754
Gnomad AMR exome
AF:
0.00446
Gnomad ASJ exome
AF:
0.00357
Gnomad EAS exome
AF:
0.00125
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000512
Gnomad OTH exome
AF:
0.00425
GnomAD4 exome
AF:
0.00246
AC:
3598
AN:
1461618
Hom.:
101
Cov.:
32
AF XY:
0.00214
AC XY:
1557
AN XY:
727110
show subpopulations
African (AFR)
AF:
0.0719
AC:
2407
AN:
33470
American (AMR)
AF:
0.00463
AC:
207
AN:
44708
Ashkenazi Jewish (ASJ)
AF:
0.00314
AC:
82
AN:
26134
East Asian (EAS)
AF:
0.000529
AC:
21
AN:
39698
South Asian (SAS)
AF:
0.000197
AC:
17
AN:
86208
European-Finnish (FIN)
AF:
0.0000187
AC:
1
AN:
53396
Middle Eastern (MID)
AF:
0.00495
AC:
28
AN:
5654
European-Non Finnish (NFE)
AF:
0.000453
AC:
504
AN:
1111966
Other (OTH)
AF:
0.00548
AC:
331
AN:
60384
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.469
Heterozygous variant carriers
0
219
438
658
877
1096
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
86
172
258
344
430
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0209
AC:
3180
AN:
152244
Hom.:
123
Cov.:
33
AF XY:
0.0196
AC XY:
1462
AN XY:
74440
show subpopulations
African (AFR)
AF:
0.0723
AC:
3001
AN:
41514
American (AMR)
AF:
0.00660
AC:
101
AN:
15302
Ashkenazi Jewish (ASJ)
AF:
0.00202
AC:
7
AN:
3468
East Asian (EAS)
AF:
0.000772
AC:
4
AN:
5178
South Asian (SAS)
AF:
0.000207
AC:
1
AN:
4828
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10618
Middle Eastern (MID)
AF:
0.0170
AC:
5
AN:
294
European-Non Finnish (NFE)
AF:
0.000588
AC:
40
AN:
68020
Other (OTH)
AF:
0.00994
AC:
21
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.501
Heterozygous variant carriers
0
149
299
448
598
747
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
36
72
108
144
180
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00833
Hom.:
107
Bravo
AF:
0.0239
TwinsUK
AF:
0.000270
AC:
1
ALSPAC
AF:
0.000259
AC:
1
ESP6500AA
AF:
0.0760
AC:
335
ESP6500EA
AF:
0.00105
AC:
9
ExAC
AF:
0.00746
AC:
906
Asia WGS
AF:
0.00289
AC:
10
AN:
3478
EpiCase
AF:
0.000654
EpiControl
AF:
0.000949

ClinVar

Significance: Benign
Submissions summary: Uncertain:1Benign:13Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Uncertain:1Benign:3
Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 30967997, 28135048, 24728327) -

Apr 29, 2016
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: The c. variant involves the alteration of a non-conserved nucleotide and 2/4 in silico tools predict a neutral outcome. The variant is present in the control population dataset of ExAC at frequency of 0.78%, predomintantly observed in the African subpopulation at a frequency of 8%, including 37 homozygous occurrences. The observed frequency greatly exceeds the maximum expected allele frequency for a pathogenic variant of 0.18%, strong evidence that it is a benign polymorphism. Classification of the variant of interest has not been reported by reputable databases/clinical laboratories. Taking together, based on the prevalence of this variant in general population the variant was classified as Benign. -

Feb 28, 2020
Leiden Open Variation Database
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:curation

Curator: Arleen D. Auerbach. Submitter to LOVD: Arleen D. Auerbach. -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

not specified Benign:3Other:1
Sep 19, 2013
ITMI
Significance:not provided
Review Status:no classification provided
Collection Method:reference population

- -

-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Mar 16, 2021
Quest Diagnostics Nichols Institute San Juan Capistrano
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Dec 05, 2016
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Fanconi anemia Benign:3
May 10, 2017
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Feb 06, 2020
Sema4, Sema4
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:curation

- -

Feb 02, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Fanconi anemia complementation group C Benign:2
Jul 07, 2023
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Malignant tumor of breast Benign:1
-
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

The FANCC p.Val449Met variant was identified in 4 of 912 proband chromosomes (frequency: 0.004) from British/other individuals or families with non-BRCA1/2 breast cancer, Fanconi anemia and leukemia, and was identified in 8 of 1362 control chromosomes from healthy individuals (Gibson 1996, Seal 2003, Barber 2003, Bodian 2014). The variant was also identified in dbSNP (ID: rs1800367) “With other allele”, ClinVar (classified as benign by Prevention Genetics and Invitae; likely benign by Illumina, and unclassified by ITMI), Clinvitae (2X), LOVD 3.0 (1X) but was not identified in Cosmic, and MutDB databases. The variant was identified in control databases in 2071 (76 homozygous) of 276492 chromosomes at a frequency of 0.007 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Consortium Feb 27, 2017) being identified in the following population at a frequency greater than 1%: African in 1753 (74 homozygous) of 23978 chromosomes (freq: 0.07), The p.Val449 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information this variant meets our laboratory's criteria to be classified as benign. -

Hereditary cancer-predisposing syndrome Benign:1
Sep 16, 2016
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.15
BayesDel_addAF
Benign
-0.58
T
BayesDel_noAF
Benign
-0.54
CADD
Benign
17
DANN
Uncertain
1.0
DEOGEN2
Benign
0.34
T;T
Eigen
Benign
-0.25
Eigen_PC
Benign
-0.48
FATHMM_MKL
Benign
0.17
N
LIST_S2
Benign
0.79
.;T
MetaRNN
Benign
0.0034
T;T
MetaSVM
Benign
-1.1
T
MutationAssessor
Benign
2.0
M;M
PhyloP100
1.1
PrimateAI
Benign
0.35
T
PROVEAN
Benign
-1.7
N;N
REVEL
Benign
0.080
Sift
Uncertain
0.011
D;D
Sift4G
Uncertain
0.0080
D;D
Polyphen
0.99
D;D
Vest4
0.41
MVP
0.57
MPC
0.27
ClinPred
0.015
T
GERP RS
1.6
Varity_R
0.052
gMVP
0.26
Mutation Taster
=98/2
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1800367; hg19: chr9-97869536; COSMIC: COSV56660124; API